Altimmune (ALT) Accumulated Depreciation (2016 - 2025)

Altimmune (ALT) has 10 years of Accumulated Depreciation data on file, last reported at $2.3 million in Q4 2025.

• Accumulated Depreciation for Q4 2025 came in at $2.3 million, up 5.06% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.3 million (up 5.06% YoY), and the FY2025 annual result was $2.3 million, up 5.06% from the prior year.
• Accumulated Depreciation rose to $2.3 million in Q4 2025 per ALT's latest filing, from $2.2 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $2.3 million in Q4 2025 and troughed at $1.1 million in Q1 2022.
• A 5-year average of $1.9 million and a median of $1.9 million in 2021 frame the typical range for Accumulated Depreciation.
• The sharpest annual moves came in 2022 and 2023: Accumulated Depreciation slumped 36.08% in 2022, then soared 31.84% in 2023.
• A 5-year view of Accumulated Depreciation shows it stood at $2.0 million in 2021, then decreased by 26.82% to $1.5 million in 2022, then surged by 31.84% to $2.0 million in 2023, then gained by 12.05% to $2.2 million in 2024, then grew by 5.06% to $2.3 million in 2025.
• Business Quant data shows ALT's Accumulated Depreciation at $2.3 million in Q4 2025, $2.2 million in Q4 2024, and $2.0 million in Q4 2023.